Transgene SA (EPA:TNG)
1.005
-0.075 (-6.94%)
At close: Nov 28, 2025
Transgene Employees
Transgene had 144 employees as of December 31, 2024. The number of employees increased by 3 or 2.13% compared to the previous year.
Employees
144
Change (1Y)
3
Growth (1Y)
2.13%
Revenue / Employee
€51,531
Profits / Employee
€250,211
Market Cap
133.06M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 144 | 3 | 2.13% |
| Dec 31, 2023 | 141 | -5 | -3.42% |
| Dec 31, 2022 | 146 | 3 | 2.10% |
| Dec 31, 2021 | 143 | 4 | 2.88% |
| Dec 31, 2020 | 139 | 3 | 2.21% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| emeis Société anonyme | 83,494 |
| Sanofi | 82,878 |
| Eurofins Scientific SE | 62,696 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 9,901 |
Transgene News
- 16 days ago - Transgene SA (TRGNF) Discusses TG4050 Phase I Immunological Data in Head and Neck Cancer from SITC Presentation Transcript - Seeking Alpha
- 2 months ago - Transgene SA (FRA:TGNA) (Half Year 2025) Earnings Call Highlights: Strategic Focus on TG4050 ... - GuruFocus
- 2 months ago - Half Year 2025 Transgene SA Earnings Call Transcript - GuruFocus
- 2 months ago - Transgene SA 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 2 months ago - Transgene SA (TRGNF) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 1 year ago - Half Year 2024 Transgene SA Earnings Call Transcript - GuruFocus
- 2 years ago - Transgene SA (TRGNF) Q2 2023 Earnings Call Transcript - Seeking Alpha
- 2 years ago - Transgene Announces New Leadership Structure to Accelerate the Development of its Innovative Immunotherapy Portfolio - Business Wire